Welcome to our dedicated page for Albemarle SEC filings (Ticker: ALB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Albemarle Corporation (NYSE: ALB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Virginia-incorporated public company with common stock listed on the NYSE, Albemarle regularly submits reports that cover financial results, material agreements, governance updates and other significant events.
Among the key documents are Form 8-K current reports, where Albemarle discloses items such as quarterly earnings releases, material definitive agreements, goodwill impairment conclusions, director and officer changes, and organizational structure updates. For example, recent 8-K filings have described the company’s third quarter results, the stock purchase agreement related to the sale of a controlling stake in Ketjen’s refining catalyst solutions business, the planned sale of its interest in the Eurecat joint venture, and changes in senior leadership roles.
Investors can also use this page to locate references to Albemarle’s use of proceeds from portfolio transactions, its assessment of impairment charges, and its classification of certain businesses as held for sale. These filings help explain how Albemarle manages its lithium, bromine and catalyst-related operations within its broader financial and strategic framework.
Stock Titan enhances access to Albemarle’s filings by pairing real-time updates from EDGAR with AI-powered summaries that highlight the main points of lengthy documents. Users can quickly understand the implications of new 8-Ks, as well as the content of other core filings such as annual and quarterly reports, and can review disclosures related to executive arrangements and board changes without reading every line of the original text.
Albemarle Corporation (ALB) – Form 4 Insider Transaction
Director James J. O’Brien reported two share acquisitions dated 1 July 2025:
- 2,725 common shares granted as the annual installment of non-employee director compensation under the company’s 2023 Stock Compensation and Deferral Election Plan. These shares are scheduled to vest on 1 July 2026.
- 37 common shares issued in lieu of cash dividends that accrued on a prior award granted 1 July 2024 and fully vested on 1 July 2025.
Both transactions were reported with a $0.00 acquisition price, indicating they are equity compensation rather than open-market purchases. Following the two grants, O’Brien’s direct beneficial ownership increased to 8,085 common shares.
No derivative securities were reported and no dispositions occurred. An Exhibit 24 Power of Attorney was filed to authorize the attorney-in-fact signature.
The filing is routine, reflecting scheduled director equity awards rather than discretionary insider buying or selling.
Albemarle Corporation (ALB) – Form 4 insider filing dated 07/03/2025
Non-employee director Alejandro Daniel Wolff reported two routine equity transactions carried out under the company’s 2023 Stock Compensation and Deferral Election Plan for Non-Employee Directors:
- Common stock dividend equivalents: 37 shares were credited on 07/01/2025 as dividend equivalents on a prior equity award that vested the same day. These shares were acquired at $0 cost, bringing the director’s directly held common stock to 12,539 shares.
- Phantom stock grant: 2,725 phantom stock units (1-for-1 convertible into common shares) were awarded on 07/01/2025. The units vest on 07/01/2026 and have no stated expiration date. Including this grant and associated dividend equivalents, the director now holds 6,278 phantom stock units.
No sales or dispositions were reported. The transactions were made at $0 price and do not involve open-market purchases or sales. As Wolff remains on the board, these grants represent standard annual director compensation and dividend accruals rather than signal-bearing insider buying or selling.
Overall, the filing reflects normal course equity accrual that slightly increases insider alignment but is immaterial to Albemarle’s share count or valuation. There is no indication of strategic intent or upcoming corporate events.
Albemarle Corporation (ALB) – Form 4 insider transaction filing
Director Dean Seavers reported two equity awards dated 1 July 2025:
- 2,725 common shares granted under the 2023 Stock Compensation and Deferral Election Plan for Non-Employee Directors; the award vests on 1 July 2026.
- 37 additional shares issued as accrued dividends on a July 2024 award that vested in full on 1 July 2025.
No shares were sold and no derivative securities were transacted. Following the awards, Seavers’ total direct beneficial ownership rose to 12,021 common shares. The transactions were effected at a stated price of $0, reflecting their nature as board compensation rather than open-market purchases.
The filing is routine for annual director compensation but does increase insider equity alignment and signals continued board participation in Albemarle’s long-term incentive structure.